Anti-inflammatory effects of tetrahydrobiopterin on early rejection in renal allografts: modulation of inducible nitric oxide synthase

ALBERT HUISMAN,* †§, INGRID VOS,† § ERNST E. VAN FAASSEN,§ JAAP A. JOLES,† HERMANN-JOSEF GRÖNE, † PAVEL MARTASEK,†† ANTON-JAN VAN ZONNEVELD,* ANATOLY F. VANIN,‡‡ AND TON J. RABELINK* §

*Department of Vascular Medicine, †Nephrology and Hypertension, and §Clinical Chemistry, University Medical Center, Utrecht, The Netherlands; ‡Department of Cellular and Molecular Pathology, German Cancer Institute, Heidelberg, Germany; ††Department of Pediatrics, Faculty of Medicine I, Charles University, Prague, Czech Republic; and ‡‡Institute of Chemical Physics, Russian Academy of Sciences, Moscow, Russia

SPECIFIC AIM

To assess whether therapy with tetrahydrobiopterin (BH4) diminishes oxygen radical stress and improves nitric oxide (NO) levels after allogenic kidney transplantation in a rat model. To relate such changes to modulation of iNOS function.

PRINCIPAL FINDINGS

1. Effect of sepiapterin on intra graft superoxide production in renal allografts

Oxidative stress is thought to play a major role in endothelial activation in transplanted organs. It has been suggested that NO synthase (NOS) enzyme can act as a source of superoxide (O2"") production in vivo. To assess the contribution of NOS-mediated O2"") production associated with early rejection of renal grafts, we performed syngenic (LEW to LEW) and allogenic (BN to LEW) kidney transplantations in rats and measured intragraft O2"") production using lucigenin-enhanced chemiluminescence. As a result of ischemia-reperfusion injury, 24 h after syngenic kidney transplantation O2"") production was modestly elevated in the isografts compared with O2"") production in nontransplanted donor kidneys. As expected, elevation of O2"") production in the allograft was much more pronounced, most likely due to the additional inflammatory reactions associated with allogenic transplantation. In both transplantation groups, we studied the effect of sepiapterin administration as a stable precursor, which is converted to BH4 in vivo. Sepiapterin could not reduce the small increase in O2"") production seen in the untreated isografts. After sepiapterin treatment, the threefold increase of O2"") production in the allograft was decreased by ~50% (Fig. 1).

2. Effect of sepiapterin on intragraft NO release

Under conditions of insufficient availability of the NOS cofactor BH4, the enzyme can directly reduce oxygen and produce O2" instead of NO. If reduction of O2" levels in the allograft by sepiapterin were due to improved NOS function, supplementation of sepiapterin in vivo should lead to a concomitant increase in the production of NO. Therefore, we measured NO levels in the allografts using the NO spin trap Fe-(DETC)2 and EPR spectroscopy. Treatment with sepiapterin improves NO bioavailability in kidney tissue twofold compared with that of untreated animals (Fig. 1).

3. Pattern of NOS protein expression

Since the effect of the NOS cofactor tetrahydrobiopterin was specific for the allografts, we evaluated the pattern of NOS expression in the allograft vs. that in isografts. Using immunohistochemical analysis of sections of 24 h renal transplants, we found that allograft transplantation was associated with iNOS expression. iNOS protein was focally expressed between the tubular structures in the inner and outer cortex in association with inflammatory cells. The constitutively expressed iNOS in renal tubuli had a similar intensity relative to the donor kidney.

4. Effect of BH4 on iNOS function

To support the hypothesis that the elevation of iNOS expression in renal allografts could contribute to elevated O2"") production, we performed in vitro experiments on recombinant iNOS using spin trap DEPMPO and EPR spectroscopy to demonstrate that iNOS can produce O2" in the absence of the cofactor BH4.

To read the full text of this article, go to http://www.fasebj.org/cgi/doi/10.1096/fj.01–0890fje; to cite this article, use FASEB J. (May 8, 2002) 10.1096/fj.01–0890fje.

Both authors contributed equally.

Correspondence: Department of Vascular Medicine, University Medical Center, P02.226, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. E-mail: t.rabelink@digd.azu.nl

0892-6638/02/0016-1135 © FASEB
Addition of NADPH (2.5 mM) to a solution containing BH₄-free iNOS (1.5 μM), calmodulin (10 μg/ml), Ca²⁺ (5 mM), l-arginine (1 mM), and DEPMPO (50 mM) resulted in formation of the paramagnetic adduct DEPMPO-OOH. Addition of BH₄ reduced the superoxide signal by ~70% but did not abolish it. We conclude that iNOS was producing O₂⁻ even under the most optimal conditions. Within the NOS enzyme, the source of O₂⁻ can be localized by addition of site selective inhibitors. Addition of the reductase domain inhibitor diphenyliodoniumchloride (200 μM) almost completely abolishes the O₂⁻ signal. In contrast, the heme domain inhibitor cyanide (10 mM), which inhibits electron flow downstream from the reductase do-

main, reduces the intensity of the O₂⁻ signal by ~70%. These observations show that heme and reductase domain act as potential sources of O₂⁻ production. As BH₄ acts only on the heme domain, this explains why BH₄ cannot totally prevent superoxide generation by iNOS. The question then arises whether iNOS can still release NO when O₂⁻ is produced at the same time. Theoretically, this may lead to ONOO⁻ production by the enzyme. In subsequent experiments using the formation of paramagnetic MNIC–MGD complexes to detect NO release from the iNOS enzyme, we found that only in the presence of adequate antioxidant capacity and of BH₄ would the iNOS enzyme release NO. If one of these two components is lacking, no NO is formed (Fig. 2). These data suggest that in an environment of sufficient antioxidant capacity, BH₄ supplementation may indeed reduce O₂⁻ and increase NO release by iNOS, as observed in our allografts.

5. Effect of sepiapterin on infiltration of inflammatory cells

We previously found that selective iNOS blockade in this transplantation model reduces inflammation. We therefore evaluated whether modulation of iNOS by the BH₄ precursor sepiapterin and its associated changes in NO/O₂⁻ production result in less inflammation of the allograft. Infiltration pattern and amount of monocytes in the renal isograft and allograft were evaluated for the entire kidney cross section using an antibody directed against the monocyte/macrophage marker ED-1. In allografts (but not in isografts), sepiapterin treatment significantly reduced monocyte/macrophage influx compared with saline (P<0.05). The mean number of monocytes/macrophages per vessel was decreased to levels seen in the saline-treated isografts.

Figure 1. NO and superoxide measurement in the kidney. A) NO determination in a rat kidney; EPR signals obtained from rat kidney after allogenic transplantation. A) Contralateral kidney of a rat injected with saline. B: Transplanted kidney of a rat treated with sepiapterin (hatched bar).** (open bars), and transplanted kidney of rats treated with saline (filled bar); vs. saline (open bar) or sepiapterin (hatched bar) treated kidney grafts in the acute (24 h) phase after allogenic transplantation (both groups n=6). O₂⁻ levels assessed by lucigenin-enhanced chemiluminescence measurements (100 μM, which was shown not to generate auto-oxidation in these tissues) is expressed as counts/(s⁻¹×10 mg dry weight⁻¹). Data are mean ± se; 1-way ANOVA; *P < 0.05 vs. saline treatment in transplanted kidney. Right: NO contents in transplanted and control rat kidney. Data shown are the means ± se, n = 5 for each group. NO content expressed as arbitrary units/g wet weight kidney tissue and as percentage of the mean value in each group. NO content assessed by addition of site selective inhibitors. Addition of the reductase domain inhibitor diphenyliodoniumchloride (200 μM) almost completely abolishes the O₂⁻ signal. In contrast, the heme domain inhibitor cyanide (10 mM), which inhibits electron flow downstream from the reductase do-

Figure 2. NO production by recombinant iNOS. Incubation of iNOS 0.75 μM at 37°C in 50 mM Tris buffer pH 7.4 containing calmodulin 10 μg/ml, CaCl₂ 5 mM, l-arginine 2 mM, BSA 25 μg/ml, NADPH 2.5 mM, and with NO traps, iron–MGD complexes (0.6 mM). Spectra were recorded at 77K. All experiments were performed in triplicate. Typical spectra are shown in the A) presence of BH₄ 1.5 μM, and SOD 200 U/ml; B) absence of SOD; C) absence of BH₄ and the presence of SOD, D) with addition of NLA 3 mM in the presence of BH₄ and SOD.
CONCLUSIONS AND SIGNIFICANCE

The present study demonstrates that 24 h after ischemia-reperfusion, the renal production of $O_2^-$ was increased in syngeneic and allogeneic renal transplants. However, in the allogeneic transplants $O_2^-$ production was higher and associated with a higher number of infiltrating monocytes/macrophages in the vessel wall and expression of the inducible form of NOS. Treatment with sepiapterin, a substrate for BH$_4$, reduced $O_2^-$ production and increased NO production in allografts but not in the isografts. This improvement of redox state of the allograft was associated with a reduction of monocyte influx in the vessel wall. Since BH$_4$ is an essential cofactor of NOS and the transplant model is characterized by activation of iNOS, we investigated the possibility that BH$_4$ could have modified the production of NO and $O_2^-$ by iNOS. Using the $O_2^-$ spin trap DEPMPO and the NO spin trap Fe–MGD complex, we could demonstrate in recombinant BH$_4$-free iNOS that cofactor-deficient iNOS is not an NO-producing enzyme but a $O_2^-$-producing enzyme. $O_2^-$ production is derived from the heme as well as the reductase domain. Although BH$_4$ can reverse $O_2^-$ production derived from the heme domain, it does not affect $O_2^-$ production by the reductase domain. Only if SOD is added and $O_2^-$ production by the reductase domain is inhibited, can the enzyme produce NO. Our renal transplant data suggest that under such conditions the iNOS enzyme may have anti-inflammatory properties.

The NOS enzymes requires optimal concentration of the cofactor BH$_4$ (and the substrate L-arginine) for their function. That the BH$_4$ precursor sepiapterin reduced $O_2^-$ production as well as increased NO production in the renal allograft strongly suggests that there was a functional deficiency of BH$_4$ in the allograft.

The observation that sepiapterin had no effect on $O_2^-$ formation or monocyte influx in the isografts is probably related to the fact that in this model of ischemia-reperfusion, $O_2^-$ production is secondary to ATP depletion, hypoxanthine formation, and subsequent $O_2^-$ production by xanthine oxidase. Any possible effect on eNOS function that may have been expected secondary to oxidative BH$_4$ degradation was probably overridden by this classical mechanism of ischemia-reperfusion-associated oxyradical formation. This observation underscores the specificity of our observations with sepiapterin in the allografts and points to a modulatory effect of BH$_4$ on iNOS function.

We also show that BH$_4$ induces a shift from $O_2^-$ production by BH$_4$-free iNOS to simultaneous NO and $O_2^-$ production by BH$_4$-repleted iNOS. When the antioxidant status of the microenvironment is insufficient to prevent the very rapid reaction between $O_2^-$ and NO, rate constant $6.7 \times 10^9 \cdot 1.9 \times 10^{10}$ (M.s)$^{-1}$, peroxynitrite formation will occur. A direct illustration is provided by NO trapping using Fe–MGD complexes. In this assay, paramagnetic MNIC-MGD is obtained only in presence of SOD, showing that the antioxidant status of the environment (i.e., SOD) determines whether enzymatic NO is sufficiently long-lived to diffuse away. These findings may help explain why inhibition of iNOS retards the development of vascular injury in models characterized by oxyradical stress (e.g., atherosclerosis and transplantation) whereas in models with ‘intact’ antioxidant capacity stimulation of iNOS mediates vasculoprotective effects.

The importance of the endothelial isoform of NO synthase has been well established. Endothelial-derived NO has been shown to be essential for vascular homeostasis and modulation of eNOS has thus become a target in prevention of cardiovascular disease. The role of iNOS in vascular biology, however, is less clear. Classically, iNOS has been regarded as an enzyme that produces nanomolar amounts of the NO radical, thereby causing cellular damage. The current study shows that iNOS can be a $O_2^-$, peroxynitrite as well as an NO-producing enzyme. The biological effects of iNOS not only depend on which radical species is released by the enzyme, but also on the antioxidant capacity of the cellular microenvironment of the enzyme (Fig. 3).